Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Synlogic Inc (SYBX)

Synlogic Inc (SYBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,493
  • Shares Outstanding, K 11,696
  • Annual Sales, $ 3,370 K
  • Annual Income, $ -57,280 K
  • EBIT $ -78 M
  • EBITDA $ -77 M
  • 60-Month Beta 0.84
  • Price/Sales 5.07
  • Price/Cash Flow N/A
  • Price/Book 1.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.10
  • Number of Estimates 1
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year -1.71
  • Growth Rate Est. (year over year) +94.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3700 +1.46%
on 11/14/24
1.6500 -15.76%
on 11/01/24
-0.0100 (-0.71%)
since 10/14/24
3-Month
1.3600 +2.21%
on 09/12/24
1.6900 -17.75%
on 09/23/24
-0.0200 (-1.42%)
since 08/14/24
52-Week
1.2200 +13.93%
on 08/12/24
5.1181 -72.84%
on 01/03/24
-0.7300 (-34.43%)
since 11/14/23

Most Recent Stories

More News
Synlogic Reports Third Quarter 2024 Financial Results

SYBX : 1.3900 (-1.43%)
Synlogic Flat on Q1 Numbers

Synlogic, Inc. (NASDAQ: SYBX) waned Tuesday, after reporting financial results for the first quarter ...

SYBX : 1.3900 (-1.43%)
Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks

/PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...

SYBX : 1.3900 (-1.43%)
DNA : 7.31 (-15.00%)
Synlogic Reports Second Quarter 2022 Financial Results and Provides Business Update

– Three clinical data readouts across three programs expected in H2 2022 – – PKU Phase 3 readiness activities underway for planned start in H1 2023 – – ...

SYBX : 1.3900 (-1.43%)
Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU)

Expected data in H2 2022 brings Synlogic to three clinical readouts this year Third candidate in less than two years to enter the clinic; Reflects...

SYBX : 1.3900 (-1.43%)
Synlogic Announces Appointment of General Counsel and Corporate Secretary

CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for...

SYBX : 1.3900 (-1.43%)
Synlogic to Present at the 2022 National PKU Alliance (NPKUA) Conference

VANCOUVER, Wash., June 28, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for...

SYBX : 1.3900 (-1.43%)
Synlogic to Present at the 2022 HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation Conference

BETHESDA, Md., June 21, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic...

SYBX : 1.3900 (-1.43%)
Synlogic Reports First Quarter 2022 Financial Results and Provides Business Update

- Clinical readouts anticipated for phenylketonuria (PKU), homocystinuria (HCU) and enteric hyperoxaluria programs in H2 2022 – - PKU program progressing...

SYBX : 1.3900 (-1.43%)
Synlogic Announces Data Presentations from Five Programs at the 2022 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference

CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for...

SYBX : 1.3900 (-1.43%)

Business Summary

Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The company's pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases such as Urea Cycle Disorder and Phenylketonuria....

See More

Key Turning Points

3rd Resistance Point 1.4833
2nd Resistance Point 1.4567
1st Resistance Point 1.4233
Last Price 1.3900
1st Support Level 1.3633
2nd Support Level 1.3367
3rd Support Level 1.3033

See More

52-Week High 5.1181
Fibonacci 61.8% 3.6290
Fibonacci 50% 3.1691
Fibonacci 38.2% 2.7091
Last Price 1.3900
52-Week Low 1.2200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar